Sankyo Pharma Expands to 57,000 SF

PARSIPPANY, NJ-Sankyo Pharma, Inc., the US subsidiary of Sankyo Co., Japan’s second largest pharmaceutical company, has signed a long-term lease for 56,954 sf at Two Hilton Court. The transaction involves the renewal of the firm’s existing 36,435-sf lease. Expansion into the new space is expected to be completed by the end of the year.

Christopher E. Kinum, principal, and F. John Fatigati, senior vice president of the Chatham, NJ-based Garibaldi Group, represented Sankyo with the original transaction, the renewal and the expansion. Michael Nevins was the in-house representative for the property’s owner, Mack-Cali Realty of Cranford, NJ. “This transaction is another indicator of New Jersey’s role in the pharmaceutical industry,” according to Fsatigati.

Sankyo develops new classes of medicines for a variety of diseases, including cancer, cardiovascular disease and metabolic disorders. Perhaps its best known brand is the cholesterol-lowering drug, WelChol.